In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatm
about
Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrheaA New, Potent, and Placenta-Permeable Macrolide Antibiotic, Solithromycin, for the Prevention and Treatment of Bacterial Infections in PregnancyCurrent and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challengeAntimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and futurePreparing for an era of untreatable gonorrheaMycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutationsThe Human Ureaplasma Species as Causative Agents of ChorioamnionitisGonorrhea - an evolving disease of the new millennium.Antibiotics in the clinical pipeline at the end of 2015.In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.The use of cephalosporins for gonorrhea: an update on the rising problem of resistance.Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011.Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic ImpairmentFuture treatment of gonorrhea--novel emerging drugs are essential and in progress?In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway.Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota.Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century.Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model.Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae in Ontario, Canada.A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea.Is gonorrhea becoming untreatable?Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Update on Treatment Options for Gonococcal Infections.New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.Drug-resistant Neisseria gonorrhoeae: latest developments.Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium.Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea.Molecular epidemiology and mechanisms of resistance of azithromycin-resistant Neisseria gonorrhoeae isolated in France during 2013-14.Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines.Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.Management of Gonorrhea in Adolescents and Adults in the United States.Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226.Determination of In Vitro Activities of Solithromycin at Different pHs and Its Intracellular Activity against Clinical Isolates of Neisseria gonorrhoeae from a Laboratory Collection.First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea?Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.Reply to “Management of Pharyngeal Gonorrhea Is Crucial To Prevent the Emergence and Spread of Antibiotic-Resistant Neisseria gonorrhoeae”.Identification and Characterization of the Neisseria gonorrhoeae MscS-like Mechanosensitive Channel.Future Prospects for Neisseria gonorrhoeae Treatment.
P2860
Q24633203-17DEB66E-D10F-4F42-A1A6-A7AFEF7C77B7Q26749565-151556B2-CE67-4276-850C-563BDF08D6FCQ26796265-D45B97F0-04D4-44C9-90BF-2448260E7F25Q26862597-D11EB3D7-8F76-4479-ABE0-4FBBD19E66C4Q27002771-9DAC1930-D06B-47FD-AE4A-335EEF477E9DQ27021073-D8A11B93-78DC-4579-A101-3BF3615E7EFEQ28067452-E29DB1BF-AA5D-41E8-9D8E-05D267E0949DQ30235031-39464501-ECF4-4061-81D2-A5B5FBC00BDAQ30249262-D6F2BAA8-E653-4EDE-96EA-20D1FF094800Q33797838-A49CFB1D-36E5-41BC-B558-090EC0AEA7CAQ33836057-FA5CE64E-A912-4BEC-9787-AD54452A579AQ34563908-86AE9FBB-2CCA-418B-8FFC-A4CDCD37EAE5Q35860106-A5261762-98BC-430C-9F76-757B15FAB937Q35998223-C991ACBA-B08E-4B81-9EDF-942020657143Q36086360-D476109A-CC31-412A-8320-777E1FFA8D1BQ36558447-1F051163-CD3F-4AEE-8F70-0E4E1CDDEF97Q37023237-069EF6BF-E53C-4DCE-AB82-00F22FB9B79AQ37036002-2E5EF456-53B4-4C45-9AC3-C776E6A88D9BQ37544439-F5F823E8-7E41-46F4-A141-9E5D5B4C223AQ37713027-17FFB72F-E6F8-43C4-A2C2-B7FD7AB16685Q37840216-9ACF3D05-3426-406D-A359-76F3819D8B97Q37844851-18075A04-682B-4D4B-88B9-7BC91C62C6AFQ38233471-599231B0-C91A-43C8-BFA8-F092712E60F4Q38581807-D39C1BE8-9EAB-4FFC-BB56-F7D698BDA0E6Q38675370-5CC89405-761F-4F1C-A044-575ADCE403D4Q38756266-5621FB1F-90E5-4165-81EE-71EA1171CCF1Q38772340-B9A6AB91-6220-4C3A-B5A4-661C23E6131FQ38793951-36AA0B74-60D6-4AF6-8368-0560DEDF2C44Q38900941-E4936128-F07F-49AE-838D-EBE15715B1A4Q39026738-280D17F7-8E92-493A-A934-3301A34965A2Q40118853-0F415F8B-4147-4AF8-BE24-5F12B80372E9Q40212540-B08BEE8E-70D2-4D3B-A1BE-40C953A33168Q40279995-A76D5339-58CB-423D-B4AF-0CA0A6275186Q40681291-97020C85-5FF2-494E-BE0F-3F6141F5FC0CQ42573047-492DE75C-A2C0-422F-86C5-945C9B0BC90DQ42693691-DCC4F840-979D-412B-839E-6188BCC43B7EQ43165331-C732EBAA-85AC-49A4-A65A-10498C52C81FQ46223391-1EFF937B-3FDB-41BE-82AC-E0643848A427Q53684891-AA1D2A9D-3E17-42F6-92EC-AEDDF6F00823Q55406005-54382955-081C-410A-B51A-96ABED7B392C
P2860
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatm
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
In vitro activity of the new f ...... l resistance: potential treatm
@ast
In vitro activity of the new f ...... l resistance: potential treatm
@en
type
label
In vitro activity of the new f ...... l resistance: potential treatm
@ast
In vitro activity of the new f ...... l resistance: potential treatm
@en
prefLabel
In vitro activity of the new f ...... l resistance: potential treatm
@ast
In vitro activity of the new f ...... l resistance: potential treatm
@en
P2093
P2860
P356
P1476
In vitro activity of the new f ...... l resistance: potential treatm
@en
P2093
Jörgen S Jensen
Makoto Ohnishi
Prabhavathi Fernandes
P2860
P304
P356
10.1128/AAC.00036-12
P407
P577
2012-02-21T00:00:00Z